Context
A constituent of Josh Newbury experienced shortages of hormone replacement therapy (HRT) drug and highlighted the low awareness among GPs about menopause, leading to ineffective treatments and private costs for women.
Question
Earlier this year, a constituent came to speak to me about shortages of the one hormone replacement therapy drug that was working for her after years of misdiagnoses and ineffective treatment. She told me that GPs have very low awareness of menopause and often recommend alternatives that cause adverse reactions, leaving her and many other women paying for private advice and treatment and taking time off work. Will the Minister update the House on what the Department is doing to address HRT shortages and to improve training for GPs so that millions of women get the support that they need?
Answer from The Parliamentary Under-Secretary of State for Health and Social Care (Dr Zubir Ahmed)
I thank my hon. Friend for highlighting this crucial issue. The majority of the more than 70 HRT products are in good supply, but we are aware of shortages affecting certain estradiol patches, and we are engaging with suppliers to expedite deliveries wherever we can. We have issued guidance to healthcare professionals under the serious shortage protocols methodology to enable community pharmacists to supply alternatives where appropriate. Furthermore, we are committed to funding research into women’s health, and we have invested approximately £5 million through the National Institute for Health and Care Research scheme into menopause research, including studies for new treatments to improve outcomes for women experiencing the menopause.
Was this summary accurate? Tell us
How accurate was this summary? (1 = poor, 5 = spot on)